Medicare does cover Wegovy in some situations, but not as a general weight‑loss drug. Coverage today is mostly tied to heart disease risk and specific medical criteria, and bigger obesity‑drug coverage changes are scheduled for 2026.

Quick Scoop: Short Answer

  • Yes, Medicare can cover Wegovy right now when it is prescribed to reduce the risk of serious cardiovascular events (like heart attack or stroke) in adults who are overweight or have obesity and already have cardiovascular disease, usually under a Part D drug plan.
  • No, Medicare does not generally cover Wegovy just for weight loss or cosmetic weight management at this time.
  • Major expansion of GLP‑1 / obesity‑drug coverage is planned starting mid‑2026 under new federal programs and pilot projects, which are expected to make drugs like Wegovy more accessible and cheaper for qualifying beneficiaries.

How Medicare Covers Wegovy Right Now

Medicare law still excludes coverage for drugs used solely for obesity, but there is an important workaround: Wegovy was approved for a cardiovascular indication.

Key points for current coverage:

  • Wegovy is now FDA‑approved to reduce risk of heart attack and stroke in people with cardiovascular disease who are overweight or have obesity.
  • Because that heart‑protection use is not explicitly excluded, Medicare Part D plans are allowed to include Wegovy on their formularies for that indication.
  • Original Medicare (Part A and Part B) typically does not pay for Wegovy, since it is a self‑injected drug taken at home; coverage runs through Part D prescription plans or Medicare Advantage plans with drug coverage.

In practice, that means:

  • Your prescriber usually must document cardiovascular disease plus qualifying BMI/weight status to meet plan criteria.
  • Many Part D plans use prior authorization and may place Wegovy on a high “specialty tier,” leading to higher copays or coinsurance until you hit annual caps.

When Medicare Won’t Cover Wegovy

Even with all the buzz around GLP‑1 drugs, Medicare is still strict about weight‑loss‑only use.

Situations where Wegovy is usually not covered:

  • Prescribed purely for weight loss without qualifying cardiovascular disease or other accepted medical indication.
  • Used as an obesity drug in people who do not meet specific medical criteria laid out by the plan (for example, missing required diagnoses or BMI thresholds).

Until the newer programs start, Medicare’s stance remains: no coverage for “cosmetic” or lifestyle weight‑loss drugs, even if they are the same GLP‑1 molecules used for diabetes.

What’s Changing in 2026 (Big Picture)

Recent federal moves and negotiated deals are set to expand access to GLP‑1 drugs, including Wegovy, for people on Medicare.

Highlights of what’s been announced or outlined:

  • A Medicare Part D pilot program beginning in 2026 is expected to cover GLP‑1 drugs for severe obesity (for example, BMI over 35) and for people who are overweight with conditions like prediabetes or cardiovascular disease, with a fixed monthly copay (early outlines mention amounts such as about 50 dollars per month).
  • Broader federal initiatives indicate Medicare and Medicaid will cover GLP‑1s, at reduced costs, for obesity‑related treatment as part of a time‑limited “test” program running into the early 2030s unless extended.
  • Negotiated drug‑price deals are projected to bring down what Medicare pays per month for these medications and create parallel discounted‑price options for people outside of traditional coverage, potentially including a federal buying portal.

These 2026+ changes are a big shift from the old “no obesity drugs” rule and are why Wegovy and similar meds are such a hot trending topic in Medicare discussions right now.

Practical Steps If You’re On Medicare

If you are trying to figure out whether your Medicare plan will cover Wegovy right now:

  1. Check your diagnosis list with your doctor
    • Confirm whether you have documented cardiovascular disease plus overweight/obesity, since that’s the main path to current Wegovy coverage.
  1. Review your Part D or Medicare Advantage formulary
    • Look up Wegovy by name and see if the plan lists it, what tier it’s on, and whether prior authorization is required.
  1. Ask about expected out‑of‑pocket costs
    • Coinsurance based on list price can run several hundred dollars per month until you hit the annual out‑of‑pocket cap, depending on how your plan handles specialty drugs.
  1. Keep an eye on 2026 plan materials
    • As the 2026 pilot and related programs roll out, Part D and Medicare Advantage plans will revise their formularies and may advertise GLP‑1 coverage as a selling point.

Information gathered from public forums or data available on the internet and portrayed here.